Press Releases

Press Releases

October 1, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) CAMBRIDGE, Mass. and BEIJING, China, Oct. 01, 2018 (GLOBE NEWSWIRE) --  BeiGene, Ltd.  (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly
September 25, 2018
BeiGene to Present at Upcoming Investor Conferences CAMBRIDGE, Mass. and BEIJING, China, Sept. 25, 2018 (GLOBE NEWSWIRE) --  BeiGene, Ltd.  (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and
September 21, 2018
BeiGene Announces Preliminary Results from the Phase 1 Clinical Trial of Zanubrutinib in Chinese Patients with B-Cell Lymphoma at Annual Meeting of the Chinese Society of Clinical Oncology BEIJING, China and CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX:
September 20, 2018
BeiGene Presents Preliminary Results on Anti-PD-1 Antibody Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors at Annual Meeting of the Chinese Society of Clinical Oncology BEIJING, China and CAMBRIDGE, Mass., Sept.